Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators conduct this prospective study and wish to elucidate the association of serial change of body composition, serum adipo-myokines and adverse effect of chemotherapy and lung cancer prognosis
Recently, the skeletal muscle was viewed as having biochemical function in additional to traditional biomechanical function. What's more important is that muscles could synthesize and release adipo-myokines during contraction. The adipo-myokines can affect muscle regeneration, muscle atrophy, muscle mass, autophagy, fatty acid oxidation and mitochondrial biosynthesis.Studies have also found that exercise can promote the function of macrophages and regulate both pro-inflammatory and anti-inflammatory phenotypes, helping the body to establish a stable immune balance.
Since body composition can illustrate malnutrition status and cancer cachexia present, and body composition can be affected by serum adipo-myokines level. Therefore, the investigators conduct this study and wish to see the association of serial body composition and serum adipo-myokines changes with lung cancer clinical outcomes and adverse effect of any anti-cancer regimen.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of white blood cell change among before, during and after cancer therapy | assessing the change of white blood cell count among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Percentage of body fat change among before, during and after cancer therapy | assessing the change of percentage of body fat among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Percentage of total body water change among before, during and after cancer therapy | assessing the change of total body water percentage among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Percentage of soft lean mass change among before, during and after cancer therapy | assessing the change of soft lean mass percentage among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Concentration of plasma CEA change among before, during and after cancer therapy | assessing the change of plasma CEA concentration among week 0, week 4 and week 12 | week 0, week 4 and week 12 after cancer theraphy |
| Concentration of plasma albumin change among before, during and after cancer therapy | assessing the change of plasma albumin concentration among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Concentration of plasma myostatin change among before, during and after cancer therapy |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. Cardiac stents or pacemakers
Not provided
Not provided
All patients who diagnosed with lung cancer including small cell and non-small cell lung cancer from 2023-03-1to 2026-02-28 will be eligible for the study. Every patients' performance status must be in 0-2 and can receive any cancer treatments including chemotherapy.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| TSENG CHIA-CHENG | Contact | +886 7 731 7123 | 8775 | cctseng@hotmail.com.tw |
| Name | Affiliation | Role |
|---|---|---|
| TSENG CHIA-CHENG | Chang Gung Memorial Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kaohsiung Chang Gung Memorial Hospital | Recruiting | Kaohsiung City | 83301 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Adipo-myokines concentrations will be checked using residual plasma specimens on the date of before therapy, 4 weeks after therapy and 12 weeks after therapy
assessing the change of plasma myostatin concentration among week 0, week 4 and week 12 |
| week 0 , week 4 and week 12 after cancer theraphy |
| Concentration of plasma FSTL-1 change among before, during and after cancer therapy | assessing the change of plasma FSTL-1 concentration among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Concentration of plasma IL-6 change among before, during and aftercancer therapy | assessing the change of plasma IL-6 concentration among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Concentration of plasma irisin change among before, during and after cancer therapy | assessing the change of plasma irisin concentration among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Concentration of plasma adiponectin change among before, during and after cancer therapy | assessing the change of plasma adiponectin concentration among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Concentration of plasma MCP-1 change among before, during and after cancer therapy | assessing the change of plasma MCP-1 concentration among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |
| Concentration of plasma aquaporin change among before, during and after cancer therapy | assessing the change of plasma aquaporin concentration among week 0, week 4 and week 12 | week 0 , week 4 and week 12 after cancer theraphy |